Edwards Lifesciences Corporation: Increased Investment in Field Resources and Patient Access Initiatives!

Edwards Lifesciences Corporation recorded robust first quarter 2024 results, demonstrating growth on numerous fronts. The company’s total sales rose by 10% to $1.6 billion against the same period last year, leading Edwards to raise its 2024 sales guidance to the high end of 8% to 10%. This highlights the company’s successful strategic direction, underscored by its substantial investments across transcatheter platforms which are addressing patient needs associated with aortic, mitral, and tricuspid diseases.